Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
about
Human polyomavirus reactivation: disease pathogenesis and treatment approachesAdverse effects of immunotherapies for multiple sclerosis: a network meta-analysisEtrolizumab for induction of remission in ulcerative colitisAnti-MAdCAM antibody for induction of remission in ulcerative colitisNatalizumab for relapsing remitting multiple sclerosisNatalizumab for induction of remission in Crohn's diseaseNatalizumab for induction of remission in Crohn's diseaseIdentification of targets and new developments in the treatment of multiple sclerosis--focus on cladribineMolecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brainNatalizumab: A new treatment for relapsing remitting multiple sclerosisEvaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathyThe role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitisStructural brain lesions in inflammatory bowel diseaseCurrent stage in inflammatory bowel disease: What is next?Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated EntitiesTreatment-related progressive multifocal leukoencephalopathy: current understanding and future stepsThe importance of mouse models to define immunovirologic determinants of progressive multifocal leukoencephalopathyBenefits versus risks of latest therapies in multiple sclerosis: a perspective reviewInflammatory pathways of importance for management of inflammatory bowel diseaseAn update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerationsProgressive multifocal leukoencephalopathy: new conceptsDesign of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarateProgressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapiesStructure-Function Analysis of the Human JC Polyomavirus Establishes the LSTc Pentasaccharide as a Functional Receptor MotifPreventive health measures in inflammatory bowel diseaseDesigning biologic selectivity for inflammatory bowel disease--role of vedolizumabRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisSevere and steroid-resistant Crohn's diseaseMonoclonal antibodies and progressive multifocal leukoencephalopathyNatalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosisThe blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targetingRisk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's DiseaseFunctional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disordersThe long and evolving relationship between viruses and multiple sclerosisInflammatory bowel diseaseProgressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.Clinical Trials in Neurovirology: Successes, Challenges, and PitfallsProgressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.Ustekinumab for the treatment of Crohn's disease.Medical management of Crohn's disease: current therapy and recent advances.
P2860
Q21285083-B5207CED-FFC8-44D1-822F-709AEB653C48Q24185820-667EBCA7-0F9C-4251-98C5-57934B7436BBQ24187269-8F5D2056-9EA1-4ED7-9202-30BD55AD3D0FQ24187593-90BC5E6A-C1AE-4ED2-8350-DD73D28EC6F8Q24235861-DD273002-B9A2-4BF1-ABB7-8988B1EE6295Q24245190-B17F4DE8-2723-45C3-A888-05175000E05AQ24246262-FA1CCB33-4C96-4D2A-B6F8-65AE21831ED9Q24597369-684A9673-017A-481E-B18E-001C6103B6D5Q24619923-84679799-E2F3-4236-9ED8-5F1AA417F235Q24683014-361F5399-6AA8-4B3B-A72A-364AACC1BD03Q24683776-49EF3BE0-0F1D-4BE6-8AA4-3949273BB546Q26748626-00ADC2B5-32D5-4943-81A0-E71685D8EF94Q26776172-2BBABA68-D727-43FE-A702-72E7DAB3B14AQ26777429-9E463911-4E55-4ED8-BA14-3BFDF753932AQ26781389-E75375F5-060E-4459-A30A-8031CECA2BBCQ26823444-F7413A0B-357F-4158-95C8-8E3812744FE6Q26859307-60FF6413-AAB4-454F-9D1A-DF0FBA2B68B4Q26999417-627A78D8-A184-4737-B757-6B7E6CAC3664Q27005445-90B6211C-FE28-4D42-9E36-4D38208C0DC8Q27009769-A7BC67B0-7377-460F-BEB5-C5B48C78DA48Q27016148-BE10187B-5714-42EF-85FB-E0D0830AB068Q27021147-A2DECF4F-EBBC-41EB-828B-A7C9B20C7A38Q27028025-EE9B5BB6-DC1F-4E52-8899-F06027388666Q27665095-4EACCCAC-2F8F-406D-A491-F7397D42754BQ28078112-8C1DE149-AE63-4D4E-AF8A-7117EECBEEADQ28083872-72D1B7C2-6C67-44DD-8165-AAFC52426CA9Q28087414-B97FB278-6538-4F71-9F4B-AAF8511ED787Q28266806-6C9D2A49-8B32-496E-8119-A7B613CD3654Q28270413-5BE9FEF8-899E-40F6-B005-77838FA5A8A6Q28277470-3F8A6585-600C-4507-8817-9EA8A0EEDC1BQ28299076-D766D208-3378-4CA0-8C15-5719A7BD191DQ28538974-E9B4C902-396C-4234-9BB1-899647B05736Q28740884-B6AF89C8-8A12-4437-B6CD-8307FA97EEBAQ29301310-824B5656-4C44-4CDD-B887-DF7CE668067AQ29616286-28245026-4298-4F45-86C9-BBFB4A4C61C2Q30245002-FAB4C4A3-4838-44CB-A731-6ED92ADB04F4Q30250271-89ED21D2-24E4-4165-8715-90DA50181FB4Q30354301-1C5A6333-9A34-438D-98BE-D5287DD5BCBCQ30390909-8A69D86E-2C47-4321-AD07-BC072A504FB9Q30450875-C36A02D6-F07B-4CE8-BE36-A91914DE0650
P2860
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
@ast
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
@en
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
@nl
type
label
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
@ast
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
@en
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
@nl
prefLabel
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
@ast
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
@en
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
@nl
P50
P3181
P356
P1476
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
@en
P2093
Bénédicte Dubois
Maja Noman
P3181
P356
10.1056/NEJMOA051586
P407
P50
P577
2005-07-28T00:00:00Z